Statin Treatment for UnruptureD Intracranial anEurysms Study

• Status: Unknown status
• Trial end date: 2021-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to identify whether there is a measurable reduction in inflammation in walls of intracranial aneurysms with oral atorvastatin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Neurosurgical Institute
• Treatments: Atorvastatin

Criteria

Inclusion Criteria:

1. Be aged 18 or over, male or non-pregnant female;

2. patients have a saccular UIA identified on imaging (CT, MRI or DSA), and the aneurysm ≥3mm;

3. patients with wall enhancement of aneurysm by MRI VWI before treatment;

4. patients who is able to understand the objective of the trial, agrees and signs the written informed consent form.

Exclusion Criteria:

1. Patient with MRI contraindications: metallic implant, contrast allergy, claustrophobia, etc.;

2. Planned treatment of the aneurysm within 6 months;

3. Patient taking the drugs, which might have an anti-inflammatory effect, such as aspirin, statin, immunosuppressive drug, etc.

4. Dyslipidemia or severely impaired liver or renal functions

5. Retreatment of recurrent aneurysm;

6. Pregnant or lactating women;

7. Patients with malignant diseases, such as liver disease, kidney disease, congestive heart failure, malignant tumors, etc;

8. Poor compliance patients.